Skip to main content Back to Top
Advertisement

2/28/2024

Potassium Phosphate Injection

Products Affected - Description

    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 65219-0056-29

Reason for the Shortage

    • American Regent has potassium phosphate injection available.
    • CMP Pharma has potassium phosphate injection available. FDA has approved some shelf-life extensions for certain lots potassium phosphate. These date extensions can be found at https://cmppharma.com/news/cmp-pharmas-potassium-phosphates-injection-receives-fda-shelf-life-extension-for-specific-lots/
    • Fresenius Kabi did not provide a reason for the shortage.
    • Pfizer has potassium phosphate injection available.

Available Products

    • Potassium Phosphate injection, American Regent, 3 mmol/mL, 15 mL vial, 25 count, NDC 00517-2102-25
    • Potassium Phosphate injection, American Regent, 3 mmol/mL, 5 mL vial, 25 count, NDC 00517-2051-25
    • Potassium Phosphate injection, American Regent, 3 mmol/mL, 50 mL vial, 25 count, NDC 00517-2505-25
    • Potassium Phosphate injection, CMP Pharma, 3 mmol/mL, 15 mL vial, 10 count, NDC 46287-0024-10
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 65219-0054-29
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 65219-0052-29
    • Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01

Estimated Resupply Dates

    • Fresenius Kabi has potassium phosphate 3 mmol/mL 50 mL vials on back order and the company estimates a release date of mid-March 2024.

Updated

Updated February 28, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.